ARCHIVES

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

DCBDC Advisors Table Gl SPORE Over Pancreatic Cancer Research Requirement

March 17, 1995

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

December 26, 2003

HRSA: Discounts Owed on Some Orphan Drug Uses

October 24, 2014

MD Anderson Expands Reach Into Florida, Ohio

September 26, 2014

In Brief: RFPs For Recompeting Frederick Contract Still Being Drafted; Panel Meets April 13

April 10, 1981

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010